POMDOCTOR Limited announced it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, scheduled for September 14-16, 2026, with a pre-recorded presentation available starting September 11, 2026. Chairman and CEO Zhenyang Shi and COO Wanmei Shi will hold one-on-one investor meetings. The accompanying investor presentation outlines the company's strategy to build a predictive healthcare data infrastructure leveraging AI, wearables, and real-world data. Key operating metrics include over 212,800 partner physicians, nearly 700,000 paying patients, and more than 3.13 million prescriptions processed. The presentation details a plan to raise US$30 million for U.S. market expansion, AI infrastructure, and wearable device production, targeting a formal U.S. launch at CES in January 2027. Financial highlights show FY2025 net revenues of RMB 399.9 million and a net loss of RMB 130.9 million. POMDOCTOR Limited is a digital healthcare company focused on advancing AI-enabled healthcare solutions.

POMDOCTOR Limited filed a proxy statement for an extraordinary general meeting on September 30, 2026, seeking shareholder approval to terminate its American Depositary Receipt (ADR) program and directly list Class A ordinary shares on Nasdaq. The filing also proposes a 10-to-1 share consolidation, reducing the number of issued shares from approximately 500 million to 50 million while increasing par value from US$0.0001 to US$0.001. These changes are scheduled to take effect simultaneously with the ADR termination and direct listing. The company operates in the health technology sector, providing digital healthcare services.

POMDOCTOR Limited announced the advancement of its healthcare data asset strategy to enhance its AI-powered chronic disease management capabilities. The company operates in the healthcare technology industry, providing AI-driven solutions for chronic disease management.

POMDOCTOR LIMITED has regained compliance with the Nasdaq minimum bid price requirement. The company achieved this status following recent actions to address the deficiency. The company operates in the healthcare technology sector.